User login
Focus on the Impact of Technology at the AATS Focus on Thoracic Surgery: Mastering Surgical Innovation 2017
October 27-28, 2017
Encore at Wynn Las Vegas
Las Vegas, Nevada, USA
Spend two days in Las Vegas learning about the technological advances that are changing the approaches to benign and malignant esophageal disease, and lung cancer and related diseases. AATS Focus on Thoracic Surgery: Mastering Surgical Innovation 2017 features the most elite experts in the field presenting the latest information on new and emerging technologies in diagnostic and therapeutic techniques, minimally invasive surgery and robotic surgeries. The meeting’s interactive format will enable attendees to incorporate technologies into their own practices, as well as see how surgical innovation can impact patient outcomes and excellence in patient care.
One session that attendees won’t want to miss is the debate on “The Optimal Route for the Introduction of New Technologies in Surgery.” Shaf Keshavjee from Toronto General Hospital will look at the “Academic Pathway” while Robert J. Cerfolio of the University of Alabama at Birmingham will present the “Industry Driven Pathway”
Program Directors
G. Alexander Patterson
David S. Sugarbaker
Program Committee
Thomas A. D’Amico
Shaf Keshavjee
James D. Luketich
Bryan F. Meyers
Scott J. Swanson
Traves D. Crabtree
Register and reserve housing at: aats.org/focus
October 27-28, 2017
Encore at Wynn Las Vegas
Las Vegas, Nevada, USA
Spend two days in Las Vegas learning about the technological advances that are changing the approaches to benign and malignant esophageal disease, and lung cancer and related diseases. AATS Focus on Thoracic Surgery: Mastering Surgical Innovation 2017 features the most elite experts in the field presenting the latest information on new and emerging technologies in diagnostic and therapeutic techniques, minimally invasive surgery and robotic surgeries. The meeting’s interactive format will enable attendees to incorporate technologies into their own practices, as well as see how surgical innovation can impact patient outcomes and excellence in patient care.
One session that attendees won’t want to miss is the debate on “The Optimal Route for the Introduction of New Technologies in Surgery.” Shaf Keshavjee from Toronto General Hospital will look at the “Academic Pathway” while Robert J. Cerfolio of the University of Alabama at Birmingham will present the “Industry Driven Pathway”
Program Directors
G. Alexander Patterson
David S. Sugarbaker
Program Committee
Thomas A. D’Amico
Shaf Keshavjee
James D. Luketich
Bryan F. Meyers
Scott J. Swanson
Traves D. Crabtree
Register and reserve housing at: aats.org/focus
October 27-28, 2017
Encore at Wynn Las Vegas
Las Vegas, Nevada, USA
Spend two days in Las Vegas learning about the technological advances that are changing the approaches to benign and malignant esophageal disease, and lung cancer and related diseases. AATS Focus on Thoracic Surgery: Mastering Surgical Innovation 2017 features the most elite experts in the field presenting the latest information on new and emerging technologies in diagnostic and therapeutic techniques, minimally invasive surgery and robotic surgeries. The meeting’s interactive format will enable attendees to incorporate technologies into their own practices, as well as see how surgical innovation can impact patient outcomes and excellence in patient care.
One session that attendees won’t want to miss is the debate on “The Optimal Route for the Introduction of New Technologies in Surgery.” Shaf Keshavjee from Toronto General Hospital will look at the “Academic Pathway” while Robert J. Cerfolio of the University of Alabama at Birmingham will present the “Industry Driven Pathway”
Program Directors
G. Alexander Patterson
David S. Sugarbaker
Program Committee
Thomas A. D’Amico
Shaf Keshavjee
James D. Luketich
Bryan F. Meyers
Scott J. Swanson
Traves D. Crabtree
Register and reserve housing at: aats.org/focus
Call for Abstracts and Videos
You are invited to submit abstracts and videos for consideration at the AATS Week 2018 events:
AATS Aortic Symposium, April 26 - 27, 2018 in New York, NY
Submission Deadline: Monday, December 18, 2017 at 11:59 p.m. Eastern Time
AATS 98th Annual Meeting, April 28 - May 1, 2018 in San Diego, CA
Submission Deadline: Sunday, October 15, 2017 at 11:59 p.m. Eastern Time
For more information, visit: www.aats.org.
You are invited to submit abstracts and videos for consideration at the AATS Week 2018 events:
AATS Aortic Symposium, April 26 - 27, 2018 in New York, NY
Submission Deadline: Monday, December 18, 2017 at 11:59 p.m. Eastern Time
AATS 98th Annual Meeting, April 28 - May 1, 2018 in San Diego, CA
Submission Deadline: Sunday, October 15, 2017 at 11:59 p.m. Eastern Time
For more information, visit: www.aats.org.
You are invited to submit abstracts and videos for consideration at the AATS Week 2018 events:
AATS Aortic Symposium, April 26 - 27, 2018 in New York, NY
Submission Deadline: Monday, December 18, 2017 at 11:59 p.m. Eastern Time
AATS 98th Annual Meeting, April 28 - May 1, 2018 in San Diego, CA
Submission Deadline: Sunday, October 15, 2017 at 11:59 p.m. Eastern Time
For more information, visit: www.aats.org.
Take Part in the First-Ever AATS Surgical Treatment of Arrhythmias and Rhythm Disorders 2017
November 17-18, 2017
Nobu Eden Roc Hotel
Miami Beach, FL USA
Attendees of the newest AATS meeting will an interactive forum that supports the exchange of information between electrophysiologists and surgeons. The AATS Surgical Treatment of Arrhythmias and Rhythm Disorders provides a comprehensive, unbiased review of the surgical treatment of cardiac arrhythmias and rhythm disorders. The meeting will cover basic underlying mechanisms, cardiac recording and mapping techniques, clinical electrophysiology, operative techniques, cardiac monitoring and appropriate follow-up.
Sessions include:
• Concomitant Ablation – How I Do it and Why
• Hybrid Ablation and Other Alternative Approaches for Lone Atrial Fibrillation
• Lead Extraction: Modern Techniques in Management of Complications
• Management of the Left Atrial Appendage
• Mechanisms of Atrial Fibrillation
• Special Issues and Controversies in Surgical Ablation
• Surgical Ablation Guidelines
• Surgical Treatment of Arrhythmias: The Basics
• Surgical Treatment of Lone Atrial Fibrillation: How I Do It
• Ventricular Tachycardia Ablation
Program Directors
Ralph J. Damiano, Jr.
A. Marc Gillinov
Program Committee
Niv Ad
Vinay Badhwar
Manuel Castella
James L. Cox
Mark LaMeir
Patrick M. McCarthy
Takashi Nitta
Harold G. Roberts
Richard Schuessler
To view the preliminary program, go to: www.aats.org/stars
November 17-18, 2017
Nobu Eden Roc Hotel
Miami Beach, FL USA
Attendees of the newest AATS meeting will an interactive forum that supports the exchange of information between electrophysiologists and surgeons. The AATS Surgical Treatment of Arrhythmias and Rhythm Disorders provides a comprehensive, unbiased review of the surgical treatment of cardiac arrhythmias and rhythm disorders. The meeting will cover basic underlying mechanisms, cardiac recording and mapping techniques, clinical electrophysiology, operative techniques, cardiac monitoring and appropriate follow-up.
Sessions include:
• Concomitant Ablation – How I Do it and Why
• Hybrid Ablation and Other Alternative Approaches for Lone Atrial Fibrillation
• Lead Extraction: Modern Techniques in Management of Complications
• Management of the Left Atrial Appendage
• Mechanisms of Atrial Fibrillation
• Special Issues and Controversies in Surgical Ablation
• Surgical Ablation Guidelines
• Surgical Treatment of Arrhythmias: The Basics
• Surgical Treatment of Lone Atrial Fibrillation: How I Do It
• Ventricular Tachycardia Ablation
Program Directors
Ralph J. Damiano, Jr.
A. Marc Gillinov
Program Committee
Niv Ad
Vinay Badhwar
Manuel Castella
James L. Cox
Mark LaMeir
Patrick M. McCarthy
Takashi Nitta
Harold G. Roberts
Richard Schuessler
To view the preliminary program, go to: www.aats.org/stars
November 17-18, 2017
Nobu Eden Roc Hotel
Miami Beach, FL USA
Attendees of the newest AATS meeting will an interactive forum that supports the exchange of information between electrophysiologists and surgeons. The AATS Surgical Treatment of Arrhythmias and Rhythm Disorders provides a comprehensive, unbiased review of the surgical treatment of cardiac arrhythmias and rhythm disorders. The meeting will cover basic underlying mechanisms, cardiac recording and mapping techniques, clinical electrophysiology, operative techniques, cardiac monitoring and appropriate follow-up.
Sessions include:
• Concomitant Ablation – How I Do it and Why
• Hybrid Ablation and Other Alternative Approaches for Lone Atrial Fibrillation
• Lead Extraction: Modern Techniques in Management of Complications
• Management of the Left Atrial Appendage
• Mechanisms of Atrial Fibrillation
• Special Issues and Controversies in Surgical Ablation
• Surgical Ablation Guidelines
• Surgical Treatment of Arrhythmias: The Basics
• Surgical Treatment of Lone Atrial Fibrillation: How I Do It
• Ventricular Tachycardia Ablation
Program Directors
Ralph J. Damiano, Jr.
A. Marc Gillinov
Program Committee
Niv Ad
Vinay Badhwar
Manuel Castella
James L. Cox
Mark LaMeir
Patrick M. McCarthy
Takashi Nitta
Harold G. Roberts
Richard Schuessler
To view the preliminary program, go to: www.aats.org/stars
Travel to Las Vegas for Next Month’s AATS Focus on Thoracic Surgery: Mastering Surgical Innovation 2017
October 27-28, 2017
Encore at Wynn Las Vegas
Las Vegas, Nevada, USA
The most elite experts in the field will be in Las Vega to present the latest information on new and emerging technologies for thoracic surgical diseases at the AATS Focus on Thoracic Surgery: Mastering Surgical Innovation 2017. The two-day meeting provides surgeons with an opportunity to learn the latest advances in diagnostic and therapeutic techniques, minimally invasive surgery and robotic surgeries.
Concentrating on two major areas that are undergoing dynamic changes due to technological advances – benign and malignant esophageal disease, and lung cancer and related diseases – the meeting features an interactive format that will enable attendees to incorporate technologies into their own practices, as well as information on how surgical innovation can impact patient outcomes and excellence in patient care.
Course Highlights Include:
• Pulmonary Nodule Localization- Best Methods
Jay M. Lee, University of California Los Angeles
• POEM for Motility Disorders and GIST Tumors
Steven R. DeMeester, The Oregon Clinic
• What is the Current Role of EBUS/EUS?
Bryan M. Burt, Baylor College of Medicine
Program Directors
G. Alexander Patterson
David S. Sugarbaker
Program Committee
Thomas A. D’Amico
Shaf Keshavjee
James D. Luketich
Bryan F. Meyers
Scott J. Swanson
Traves D. Crabtree
To register and reserve housing, go to: aats.org/focus
October 27-28, 2017
Encore at Wynn Las Vegas
Las Vegas, Nevada, USA
The most elite experts in the field will be in Las Vega to present the latest information on new and emerging technologies for thoracic surgical diseases at the AATS Focus on Thoracic Surgery: Mastering Surgical Innovation 2017. The two-day meeting provides surgeons with an opportunity to learn the latest advances in diagnostic and therapeutic techniques, minimally invasive surgery and robotic surgeries.
Concentrating on two major areas that are undergoing dynamic changes due to technological advances – benign and malignant esophageal disease, and lung cancer and related diseases – the meeting features an interactive format that will enable attendees to incorporate technologies into their own practices, as well as information on how surgical innovation can impact patient outcomes and excellence in patient care.
Course Highlights Include:
• Pulmonary Nodule Localization- Best Methods
Jay M. Lee, University of California Los Angeles
• POEM for Motility Disorders and GIST Tumors
Steven R. DeMeester, The Oregon Clinic
• What is the Current Role of EBUS/EUS?
Bryan M. Burt, Baylor College of Medicine
Program Directors
G. Alexander Patterson
David S. Sugarbaker
Program Committee
Thomas A. D’Amico
Shaf Keshavjee
James D. Luketich
Bryan F. Meyers
Scott J. Swanson
Traves D. Crabtree
To register and reserve housing, go to: aats.org/focus
October 27-28, 2017
Encore at Wynn Las Vegas
Las Vegas, Nevada, USA
The most elite experts in the field will be in Las Vega to present the latest information on new and emerging technologies for thoracic surgical diseases at the AATS Focus on Thoracic Surgery: Mastering Surgical Innovation 2017. The two-day meeting provides surgeons with an opportunity to learn the latest advances in diagnostic and therapeutic techniques, minimally invasive surgery and robotic surgeries.
Concentrating on two major areas that are undergoing dynamic changes due to technological advances – benign and malignant esophageal disease, and lung cancer and related diseases – the meeting features an interactive format that will enable attendees to incorporate technologies into their own practices, as well as information on how surgical innovation can impact patient outcomes and excellence in patient care.
Course Highlights Include:
• Pulmonary Nodule Localization- Best Methods
Jay M. Lee, University of California Los Angeles
• POEM for Motility Disorders and GIST Tumors
Steven R. DeMeester, The Oregon Clinic
• What is the Current Role of EBUS/EUS?
Bryan M. Burt, Baylor College of Medicine
Program Directors
G. Alexander Patterson
David S. Sugarbaker
Program Committee
Thomas A. D’Amico
Shaf Keshavjee
James D. Luketich
Bryan F. Meyers
Scott J. Swanson
Traves D. Crabtree
To register and reserve housing, go to: aats.org/focus
There is Still Time to Register for the Heart Valve Summit: Medical, Surgical and Interventional Decision Making
October 5-7, 2017
Radisson Blu Aqua Hotel
Chicago, IL, USA
Be in Chicago as the renowned faculty on the cutting edge of clinically relevant data for valvular heart disease management leads this interdisciplinary course that combines the most relevant medical, surgical and interventional options for patient care. The American College of Cardiology and the American Association for Thoracic Surgery are once again bringing together cardiologists and surgeons in a cooperative, case-based course to address the rapid advances in the treatment of valvular heart disease.
With the tradition of interactivity and practical decision making, the unique Heart Valve Summit is designed to engage participants in discussions, debates and potential controversies surrounding real-world cases.
The Heart Valve Summit will highlight:
• Basics of the Aortic Valve
• Cardiac Network Trials
• Decision Making: Recurrent Mitral Valve Regurgitation
• Degenerative Mitral Anatomy and Physiology
• Difficult Choices and Scenarios
• Ischemic Mitral Regurgitation
• Mitral Endocarditis
• Mitral Valve Replacement
• Preparing for the Future in Mitral Valve Treatment
• TAVR
• The Future of Transcatheter Mitral Interventions
• Transcatheter Aortic Valve Replacement - Indications and Devices
• The Asymptomatic Patient with Advanced Valve Disease
• Treatment of Aortic Valve Disease
• Valve Disease and the Right Ventricle
Course Directors
David H. Adams
Steven F. Bolling
Robert O. Bonow
Howard C. Herrmann
Nurse Planner
Michele Mistovich
To register and reserve housing, visit: www.aats.org/valve
October 5-7, 2017
Radisson Blu Aqua Hotel
Chicago, IL, USA
Be in Chicago as the renowned faculty on the cutting edge of clinically relevant data for valvular heart disease management leads this interdisciplinary course that combines the most relevant medical, surgical and interventional options for patient care. The American College of Cardiology and the American Association for Thoracic Surgery are once again bringing together cardiologists and surgeons in a cooperative, case-based course to address the rapid advances in the treatment of valvular heart disease.
With the tradition of interactivity and practical decision making, the unique Heart Valve Summit is designed to engage participants in discussions, debates and potential controversies surrounding real-world cases.
The Heart Valve Summit will highlight:
• Basics of the Aortic Valve
• Cardiac Network Trials
• Decision Making: Recurrent Mitral Valve Regurgitation
• Degenerative Mitral Anatomy and Physiology
• Difficult Choices and Scenarios
• Ischemic Mitral Regurgitation
• Mitral Endocarditis
• Mitral Valve Replacement
• Preparing for the Future in Mitral Valve Treatment
• TAVR
• The Future of Transcatheter Mitral Interventions
• Transcatheter Aortic Valve Replacement - Indications and Devices
• The Asymptomatic Patient with Advanced Valve Disease
• Treatment of Aortic Valve Disease
• Valve Disease and the Right Ventricle
Course Directors
David H. Adams
Steven F. Bolling
Robert O. Bonow
Howard C. Herrmann
Nurse Planner
Michele Mistovich
To register and reserve housing, visit: www.aats.org/valve
October 5-7, 2017
Radisson Blu Aqua Hotel
Chicago, IL, USA
Be in Chicago as the renowned faculty on the cutting edge of clinically relevant data for valvular heart disease management leads this interdisciplinary course that combines the most relevant medical, surgical and interventional options for patient care. The American College of Cardiology and the American Association for Thoracic Surgery are once again bringing together cardiologists and surgeons in a cooperative, case-based course to address the rapid advances in the treatment of valvular heart disease.
With the tradition of interactivity and practical decision making, the unique Heart Valve Summit is designed to engage participants in discussions, debates and potential controversies surrounding real-world cases.
The Heart Valve Summit will highlight:
• Basics of the Aortic Valve
• Cardiac Network Trials
• Decision Making: Recurrent Mitral Valve Regurgitation
• Degenerative Mitral Anatomy and Physiology
• Difficult Choices and Scenarios
• Ischemic Mitral Regurgitation
• Mitral Endocarditis
• Mitral Valve Replacement
• Preparing for the Future in Mitral Valve Treatment
• TAVR
• The Future of Transcatheter Mitral Interventions
• Transcatheter Aortic Valve Replacement - Indications and Devices
• The Asymptomatic Patient with Advanced Valve Disease
• Treatment of Aortic Valve Disease
• Valve Disease and the Right Ventricle
Course Directors
David H. Adams
Steven F. Bolling
Robert O. Bonow
Howard C. Herrmann
Nurse Planner
Michele Mistovich
To register and reserve housing, visit: www.aats.org/valve
Orsiro coronary DES outperforms Xience
BARCELONA – A new model of drug-eluting coronary stent outperformed the reigning benchmark Xience stent in a head-to-head, pivotal comparison with 1,334 patients.
The results “advance a new standard for drug eluting stents,” David E. Kandzari, MD, said at the annual congress of the European Society of Cardiology. The trial tested the Orsiro stent, which features very thin, 60-micron-thick cobalt chromium struts, a bioresorbable polymer, and sirolimus as the antiproliferative drug that’s released during the first 90 days of stent placement.
“To our knowledge, this is the only trial that has demonstrated superiority [of a new stent] to the Xience drug-eluting stent in a large, randomized trial. This is a landmark in interventional cardiology that raises the bar for future comparisons” of drug eluting coronary stents, Dr. Kandzari said in an interview.
The study’s primary endpoint of target lesion failure after 12 months of follow-up – a rate that combined the incidence of cardiovascular death, target-vessel related MI, and ischemia-driven target-lesion revascularization – stood at 6.2% for the 884 patients treated with the Orsiro stent and 9.6% of the 450 randomized to treatment with the Xience stent, which has struts that are 81 microns wide, and a durable polymer that releases everolimus as the antiproliferative drug.
The difference in the primary endpoint was driven primarily by a 3.6% absolute difference in the rate of target-vessel related MIs, a statistically significant difference, plus the Orsiro-treated patients showed numerically smaller rates of cardiac death and ischemia-driven target lesion revascularization, although the between-group differences for each of these two endpoints were not statistically significant. The Orsiro stent also showed a significantly reduced rate of late stent thrombosis, occurring during day 31 through 1 year, a 0.1% rate in the Orsiro-treated patients and a 0.9% rate in those who received Xience stents.
“These are remarkable results,” said Michael Haude, MD, an interventional cardiologist at Lukas Hospital in Neuss, Germany, and a cochair of the session in which Dr. Kandzari gave his report.
These results from the Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions (BIOFLOW-V) trial will be the centerpiece of an application for U.S. marketing approval for the Orsiro stent, Dr. Kandzari said. The BIOFLOW-V trial enrolled patients at 90 centers in 13 countries including the United States.
Concurrently with his report, the results were published online (Lancet. 2017 Aug 26. doi: 10.1016/S0140-6736[17]32249-3).
The potential advantage of a thinner-strut drug eluting stent showed up during the initial treatment phase, with a procedural success rate of 94% using the Orsiro stent and 90% with the Xience stent. This difference in procedural success seemed largely the result of an increased rate of periprocedural MIs, a difference that might be explained by the difference in strut thickness, said Dr. Kandzari, of Piedmont Heart Institute, Atlanta. Based on this success, designers of future drug-eluting stents may focus on thinner-strut models, he suggested.
An additional analysis that Dr. Kandzari reported combined results from two prior randomized comparisons of the Orsiro and Xience stents, creating a pooled analysis with 2,208 patients. This Bayesian analysis calculated a 100% probability of noninferiority of the Orsiro stent compared with the Xience stent, and a 97% probability of superiority. This 97% probability of superiority fell just short of the 97.5% threshold for establishing superiority that Dr. Kandzari and his associates had prespecified for this analysis.
[email protected]
On Twitter @mitchelzoler
BARCELONA – A new model of drug-eluting coronary stent outperformed the reigning benchmark Xience stent in a head-to-head, pivotal comparison with 1,334 patients.
The results “advance a new standard for drug eluting stents,” David E. Kandzari, MD, said at the annual congress of the European Society of Cardiology. The trial tested the Orsiro stent, which features very thin, 60-micron-thick cobalt chromium struts, a bioresorbable polymer, and sirolimus as the antiproliferative drug that’s released during the first 90 days of stent placement.
“To our knowledge, this is the only trial that has demonstrated superiority [of a new stent] to the Xience drug-eluting stent in a large, randomized trial. This is a landmark in interventional cardiology that raises the bar for future comparisons” of drug eluting coronary stents, Dr. Kandzari said in an interview.
The study’s primary endpoint of target lesion failure after 12 months of follow-up – a rate that combined the incidence of cardiovascular death, target-vessel related MI, and ischemia-driven target-lesion revascularization – stood at 6.2% for the 884 patients treated with the Orsiro stent and 9.6% of the 450 randomized to treatment with the Xience stent, which has struts that are 81 microns wide, and a durable polymer that releases everolimus as the antiproliferative drug.
The difference in the primary endpoint was driven primarily by a 3.6% absolute difference in the rate of target-vessel related MIs, a statistically significant difference, plus the Orsiro-treated patients showed numerically smaller rates of cardiac death and ischemia-driven target lesion revascularization, although the between-group differences for each of these two endpoints were not statistically significant. The Orsiro stent also showed a significantly reduced rate of late stent thrombosis, occurring during day 31 through 1 year, a 0.1% rate in the Orsiro-treated patients and a 0.9% rate in those who received Xience stents.
“These are remarkable results,” said Michael Haude, MD, an interventional cardiologist at Lukas Hospital in Neuss, Germany, and a cochair of the session in which Dr. Kandzari gave his report.
These results from the Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions (BIOFLOW-V) trial will be the centerpiece of an application for U.S. marketing approval for the Orsiro stent, Dr. Kandzari said. The BIOFLOW-V trial enrolled patients at 90 centers in 13 countries including the United States.
Concurrently with his report, the results were published online (Lancet. 2017 Aug 26. doi: 10.1016/S0140-6736[17]32249-3).
The potential advantage of a thinner-strut drug eluting stent showed up during the initial treatment phase, with a procedural success rate of 94% using the Orsiro stent and 90% with the Xience stent. This difference in procedural success seemed largely the result of an increased rate of periprocedural MIs, a difference that might be explained by the difference in strut thickness, said Dr. Kandzari, of Piedmont Heart Institute, Atlanta. Based on this success, designers of future drug-eluting stents may focus on thinner-strut models, he suggested.
An additional analysis that Dr. Kandzari reported combined results from two prior randomized comparisons of the Orsiro and Xience stents, creating a pooled analysis with 2,208 patients. This Bayesian analysis calculated a 100% probability of noninferiority of the Orsiro stent compared with the Xience stent, and a 97% probability of superiority. This 97% probability of superiority fell just short of the 97.5% threshold for establishing superiority that Dr. Kandzari and his associates had prespecified for this analysis.
[email protected]
On Twitter @mitchelzoler
BARCELONA – A new model of drug-eluting coronary stent outperformed the reigning benchmark Xience stent in a head-to-head, pivotal comparison with 1,334 patients.
The results “advance a new standard for drug eluting stents,” David E. Kandzari, MD, said at the annual congress of the European Society of Cardiology. The trial tested the Orsiro stent, which features very thin, 60-micron-thick cobalt chromium struts, a bioresorbable polymer, and sirolimus as the antiproliferative drug that’s released during the first 90 days of stent placement.
“To our knowledge, this is the only trial that has demonstrated superiority [of a new stent] to the Xience drug-eluting stent in a large, randomized trial. This is a landmark in interventional cardiology that raises the bar for future comparisons” of drug eluting coronary stents, Dr. Kandzari said in an interview.
The study’s primary endpoint of target lesion failure after 12 months of follow-up – a rate that combined the incidence of cardiovascular death, target-vessel related MI, and ischemia-driven target-lesion revascularization – stood at 6.2% for the 884 patients treated with the Orsiro stent and 9.6% of the 450 randomized to treatment with the Xience stent, which has struts that are 81 microns wide, and a durable polymer that releases everolimus as the antiproliferative drug.
The difference in the primary endpoint was driven primarily by a 3.6% absolute difference in the rate of target-vessel related MIs, a statistically significant difference, plus the Orsiro-treated patients showed numerically smaller rates of cardiac death and ischemia-driven target lesion revascularization, although the between-group differences for each of these two endpoints were not statistically significant. The Orsiro stent also showed a significantly reduced rate of late stent thrombosis, occurring during day 31 through 1 year, a 0.1% rate in the Orsiro-treated patients and a 0.9% rate in those who received Xience stents.
“These are remarkable results,” said Michael Haude, MD, an interventional cardiologist at Lukas Hospital in Neuss, Germany, and a cochair of the session in which Dr. Kandzari gave his report.
These results from the Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions (BIOFLOW-V) trial will be the centerpiece of an application for U.S. marketing approval for the Orsiro stent, Dr. Kandzari said. The BIOFLOW-V trial enrolled patients at 90 centers in 13 countries including the United States.
Concurrently with his report, the results were published online (Lancet. 2017 Aug 26. doi: 10.1016/S0140-6736[17]32249-3).
The potential advantage of a thinner-strut drug eluting stent showed up during the initial treatment phase, with a procedural success rate of 94% using the Orsiro stent and 90% with the Xience stent. This difference in procedural success seemed largely the result of an increased rate of periprocedural MIs, a difference that might be explained by the difference in strut thickness, said Dr. Kandzari, of Piedmont Heart Institute, Atlanta. Based on this success, designers of future drug-eluting stents may focus on thinner-strut models, he suggested.
An additional analysis that Dr. Kandzari reported combined results from two prior randomized comparisons of the Orsiro and Xience stents, creating a pooled analysis with 2,208 patients. This Bayesian analysis calculated a 100% probability of noninferiority of the Orsiro stent compared with the Xience stent, and a 97% probability of superiority. This 97% probability of superiority fell just short of the 97.5% threshold for establishing superiority that Dr. Kandzari and his associates had prespecified for this analysis.
[email protected]
On Twitter @mitchelzoler
AT THE ESC CONGRESS 2017
Key clinical point:
Major finding: The target-lesion failure rate after 12 months was 6.2% with the Orsiro stent and 9.6% with the Xience stent.
Data source: BIOFLOW-V, a multicenter, randomized trial with 1,334 patients.
Disclosures: BIOFLOW-V was sponsored by Biotronik, the company that markets the Orsiro stent. Dr. Kandzari has been a consultant to and/or has received research funding from Biotronik, Boston Scientific, Medtronic, Micell Technologies, Abbott Vascular, St. Jude, Medinol, and OrbusNeich. Dr. Haude has been a consultant to and has received honoraria from Biotronik and from several other device and drug companies.
Advance Your Knowledge at the 2017 AATS International Cardiovascular Symposium
December 8-9, 2017
Renaissance São Paulo Hotel
São Paulo, Brazil
Join renowned cardiologists and surgeons at the 2017 AATS International Cardiovascular Symposium in São Paulo, Brazil, on December 8-9, 2017, to advance your clinical knowledge in heart valve disease — aortic and ascending aorta, coronary, mitral, pulmonary and tricuspid.
The two-day symposium will bring together international leaders to discuss state-of the-art information on devices, long-term results and surgical techniques with a focus on preventing, diagnosing and treating heart valve disease. The meeting will have Spanish and Portuguese translations available.
Program Directors
Joseph S. Coselli
Walter J. Gomes
Marc R. Moon
Thoralf M. Sundt III
Registration and Housing now available, go to: aats.org/ics
December 8-9, 2017
Renaissance São Paulo Hotel
São Paulo, Brazil
Join renowned cardiologists and surgeons at the 2017 AATS International Cardiovascular Symposium in São Paulo, Brazil, on December 8-9, 2017, to advance your clinical knowledge in heart valve disease — aortic and ascending aorta, coronary, mitral, pulmonary and tricuspid.
The two-day symposium will bring together international leaders to discuss state-of the-art information on devices, long-term results and surgical techniques with a focus on preventing, diagnosing and treating heart valve disease. The meeting will have Spanish and Portuguese translations available.
Program Directors
Joseph S. Coselli
Walter J. Gomes
Marc R. Moon
Thoralf M. Sundt III
Registration and Housing now available, go to: aats.org/ics
December 8-9, 2017
Renaissance São Paulo Hotel
São Paulo, Brazil
Join renowned cardiologists and surgeons at the 2017 AATS International Cardiovascular Symposium in São Paulo, Brazil, on December 8-9, 2017, to advance your clinical knowledge in heart valve disease — aortic and ascending aorta, coronary, mitral, pulmonary and tricuspid.
The two-day symposium will bring together international leaders to discuss state-of the-art information on devices, long-term results and surgical techniques with a focus on preventing, diagnosing and treating heart valve disease. The meeting will have Spanish and Portuguese translations available.
Program Directors
Joseph S. Coselli
Walter J. Gomes
Marc R. Moon
Thoralf M. Sundt III
Registration and Housing now available, go to: aats.org/ics
Head to Miami for the AATS Surgical Treatment of Arrhythmias and Rhythm Disorders 2017
November 17-18, 2017
Nobu Eden Roc Hotel
Miami Beach, FL USA
Don’t miss this two-day, interactive forum that supports the exchange of information between electrophysiologists and surgeons. The AATS Surgical Treatment of Arrhythmias and Rhythm Disorders provides a comprehensive, unbiased review of the surgical treatment of cardiac arrhythmias and rhythm disorders. The meeting will cover basic underlying mechanisms, cardiac recording and mapping techniques, clinical electrophysiology, operative techniques, cardiac monitoring and appropriate follow-up.
Sessions include:
• Concomitant Ablation – How I Do it and Why
• Hybrid Ablation and Other Alternative Approaches for Lone Atrial Fibrillation
• Lead Extraction: Modern Techniques in Management of Complications
• Management of the Left Atrial Appendage
• Mechanisms of Atrial Fibrillation
• Special Issues and Controversies in Surgical Ablation
• Surgical Ablation Guidelines
• Surgical Treatment of Arrhythmias: The Basics
• Surgical Treatment of Lone Atrial Fibrillation: How I Do It
• Ventricular Tachycardia Ablation
Program Directors
Ralph J. Damiano, Jr.
A. Marc Gillinov
Program Committee
Niv Ad
Vinay Badhwar
Manuel Castella
James L. Cox
Mark LaMeir
Patrick M. McCarthy
Takashi Nitta
Harold G. Roberts
Richard Schuessler
To register and reserve housing, go to: www.aats.org/stars
November 17-18, 2017
Nobu Eden Roc Hotel
Miami Beach, FL USA
Don’t miss this two-day, interactive forum that supports the exchange of information between electrophysiologists and surgeons. The AATS Surgical Treatment of Arrhythmias and Rhythm Disorders provides a comprehensive, unbiased review of the surgical treatment of cardiac arrhythmias and rhythm disorders. The meeting will cover basic underlying mechanisms, cardiac recording and mapping techniques, clinical electrophysiology, operative techniques, cardiac monitoring and appropriate follow-up.
Sessions include:
• Concomitant Ablation – How I Do it and Why
• Hybrid Ablation and Other Alternative Approaches for Lone Atrial Fibrillation
• Lead Extraction: Modern Techniques in Management of Complications
• Management of the Left Atrial Appendage
• Mechanisms of Atrial Fibrillation
• Special Issues and Controversies in Surgical Ablation
• Surgical Ablation Guidelines
• Surgical Treatment of Arrhythmias: The Basics
• Surgical Treatment of Lone Atrial Fibrillation: How I Do It
• Ventricular Tachycardia Ablation
Program Directors
Ralph J. Damiano, Jr.
A. Marc Gillinov
Program Committee
Niv Ad
Vinay Badhwar
Manuel Castella
James L. Cox
Mark LaMeir
Patrick M. McCarthy
Takashi Nitta
Harold G. Roberts
Richard Schuessler
To register and reserve housing, go to: www.aats.org/stars
November 17-18, 2017
Nobu Eden Roc Hotel
Miami Beach, FL USA
Don’t miss this two-day, interactive forum that supports the exchange of information between electrophysiologists and surgeons. The AATS Surgical Treatment of Arrhythmias and Rhythm Disorders provides a comprehensive, unbiased review of the surgical treatment of cardiac arrhythmias and rhythm disorders. The meeting will cover basic underlying mechanisms, cardiac recording and mapping techniques, clinical electrophysiology, operative techniques, cardiac monitoring and appropriate follow-up.
Sessions include:
• Concomitant Ablation – How I Do it and Why
• Hybrid Ablation and Other Alternative Approaches for Lone Atrial Fibrillation
• Lead Extraction: Modern Techniques in Management of Complications
• Management of the Left Atrial Appendage
• Mechanisms of Atrial Fibrillation
• Special Issues and Controversies in Surgical Ablation
• Surgical Ablation Guidelines
• Surgical Treatment of Arrhythmias: The Basics
• Surgical Treatment of Lone Atrial Fibrillation: How I Do It
• Ventricular Tachycardia Ablation
Program Directors
Ralph J. Damiano, Jr.
A. Marc Gillinov
Program Committee
Niv Ad
Vinay Badhwar
Manuel Castella
James L. Cox
Mark LaMeir
Patrick M. McCarthy
Takashi Nitta
Harold G. Roberts
Richard Schuessler
To register and reserve housing, go to: www.aats.org/stars
Learn About the Latest Technologies at AATS Focus on Thoracic Surgery: Mastering Surgical Innovation 2017
October 27-28, 2017
Encore at Wynn Las Vegas
Las Vegas, Nevada, USA
The most elite experts in the field will be presenting the latest information on new and emerging technologies for thoracic surgical diseases at the AATS Focus on Thoracic Surgery: Mastering Surgical Innovation 2017. The two-day meeting in Las Vegas provides surgeons with an opportunity to learn the latest advances in diagnostic and therapeutic techniques, minimally invasive surgery and robotic surgeries.
Concentrating on two major areas that are undergoing dynamic changes due to technological advances – benign and malignant esophageal disease, and lung cancer and related diseases – the sessions will not only give attendees insight into the latest innovations but also includes an interactive format that will enable them to incorporate these technologies into their own practices, and information on how surgical innovation can impact patient outcomes and excellence in patient care.
Program Directors
G. Alexander Patterson
David S. Sugarbaker
Program Committee
Thomas A. D’Amico
Shaf Keshavjee
James D. Luketich
Bryan F. Meyers
Scott J. Swanson
Traves D. Crabtree
To register and reserve housing, go to: aats.org/focus
October 27-28, 2017
Encore at Wynn Las Vegas
Las Vegas, Nevada, USA
The most elite experts in the field will be presenting the latest information on new and emerging technologies for thoracic surgical diseases at the AATS Focus on Thoracic Surgery: Mastering Surgical Innovation 2017. The two-day meeting in Las Vegas provides surgeons with an opportunity to learn the latest advances in diagnostic and therapeutic techniques, minimally invasive surgery and robotic surgeries.
Concentrating on two major areas that are undergoing dynamic changes due to technological advances – benign and malignant esophageal disease, and lung cancer and related diseases – the sessions will not only give attendees insight into the latest innovations but also includes an interactive format that will enable them to incorporate these technologies into their own practices, and information on how surgical innovation can impact patient outcomes and excellence in patient care.
Program Directors
G. Alexander Patterson
David S. Sugarbaker
Program Committee
Thomas A. D’Amico
Shaf Keshavjee
James D. Luketich
Bryan F. Meyers
Scott J. Swanson
Traves D. Crabtree
To register and reserve housing, go to: aats.org/focus
October 27-28, 2017
Encore at Wynn Las Vegas
Las Vegas, Nevada, USA
The most elite experts in the field will be presenting the latest information on new and emerging technologies for thoracic surgical diseases at the AATS Focus on Thoracic Surgery: Mastering Surgical Innovation 2017. The two-day meeting in Las Vegas provides surgeons with an opportunity to learn the latest advances in diagnostic and therapeutic techniques, minimally invasive surgery and robotic surgeries.
Concentrating on two major areas that are undergoing dynamic changes due to technological advances – benign and malignant esophageal disease, and lung cancer and related diseases – the sessions will not only give attendees insight into the latest innovations but also includes an interactive format that will enable them to incorporate these technologies into their own practices, and information on how surgical innovation can impact patient outcomes and excellence in patient care.
Program Directors
G. Alexander Patterson
David S. Sugarbaker
Program Committee
Thomas A. D’Amico
Shaf Keshavjee
James D. Luketich
Bryan F. Meyers
Scott J. Swanson
Traves D. Crabtree
To register and reserve housing, go to: aats.org/focus
Register for the Heart Valve Summit: Medical, Surgical and Interventional Decision Making
October 5-7, 2017
Radisson Blu Aqua Hotel
Chicago, IL, USA
The American College of Cardiology and the American Association for Thoracic Surgery are once again bringing together cardiologists and surgeons in a cooperative, case-based course to address the rapid advances in the treatment of valvular heart disease.
With the tradition of interactivity and practical decision making, the unique Heart Valve Summit is designed to engage participants in discussions, debates and potential controversies surrounding real-world cases. A renowned faculty on the cutting edge of clinically relevant data for valvular heart disease management will lead this interdisciplinary course that combines the most relevant medical, surgical and interventional options for patient care.
The Heart Valve Summit will highlight:
• Basics of the Aortic Valve
• Cardiac Network Trials
• Decision Making: Recurrent Mitral Valve Regurgitation
• Degenerative Mitral Anatomy and Physiology
• Difficult Choices and Scenarios
• Ischemic Mitral Regurgitation
• Mitral Endocarditis
• Mitral Valve Replacement
• Preparing for the Future in Mitral Valve Treatment
• TAVR
• The Future of Transcatheter Mitral Interventions
• Transcatheter Aortic Valve Replacement - Indications and Devices
• The Asymptomatic Patient with Advanced Valve Disease
• Treatment of Aortic Valve Disease
• Valve Disease and the Right Ventricle
Course Directors
David H. Adams
Steven F. Bolling
Robert O. Bonow
Howard C. Herrmann
Nurse Planner
Michele Mistovich
To register and reserve housing, visit:
www.aats.org/valve
October 5-7, 2017
Radisson Blu Aqua Hotel
Chicago, IL, USA
The American College of Cardiology and the American Association for Thoracic Surgery are once again bringing together cardiologists and surgeons in a cooperative, case-based course to address the rapid advances in the treatment of valvular heart disease.
With the tradition of interactivity and practical decision making, the unique Heart Valve Summit is designed to engage participants in discussions, debates and potential controversies surrounding real-world cases. A renowned faculty on the cutting edge of clinically relevant data for valvular heart disease management will lead this interdisciplinary course that combines the most relevant medical, surgical and interventional options for patient care.
The Heart Valve Summit will highlight:
• Basics of the Aortic Valve
• Cardiac Network Trials
• Decision Making: Recurrent Mitral Valve Regurgitation
• Degenerative Mitral Anatomy and Physiology
• Difficult Choices and Scenarios
• Ischemic Mitral Regurgitation
• Mitral Endocarditis
• Mitral Valve Replacement
• Preparing for the Future in Mitral Valve Treatment
• TAVR
• The Future of Transcatheter Mitral Interventions
• Transcatheter Aortic Valve Replacement - Indications and Devices
• The Asymptomatic Patient with Advanced Valve Disease
• Treatment of Aortic Valve Disease
• Valve Disease and the Right Ventricle
Course Directors
David H. Adams
Steven F. Bolling
Robert O. Bonow
Howard C. Herrmann
Nurse Planner
Michele Mistovich
To register and reserve housing, visit:
www.aats.org/valve
October 5-7, 2017
Radisson Blu Aqua Hotel
Chicago, IL, USA
The American College of Cardiology and the American Association for Thoracic Surgery are once again bringing together cardiologists and surgeons in a cooperative, case-based course to address the rapid advances in the treatment of valvular heart disease.
With the tradition of interactivity and practical decision making, the unique Heart Valve Summit is designed to engage participants in discussions, debates and potential controversies surrounding real-world cases. A renowned faculty on the cutting edge of clinically relevant data for valvular heart disease management will lead this interdisciplinary course that combines the most relevant medical, surgical and interventional options for patient care.
The Heart Valve Summit will highlight:
• Basics of the Aortic Valve
• Cardiac Network Trials
• Decision Making: Recurrent Mitral Valve Regurgitation
• Degenerative Mitral Anatomy and Physiology
• Difficult Choices and Scenarios
• Ischemic Mitral Regurgitation
• Mitral Endocarditis
• Mitral Valve Replacement
• Preparing for the Future in Mitral Valve Treatment
• TAVR
• The Future of Transcatheter Mitral Interventions
• Transcatheter Aortic Valve Replacement - Indications and Devices
• The Asymptomatic Patient with Advanced Valve Disease
• Treatment of Aortic Valve Disease
• Valve Disease and the Right Ventricle
Course Directors
David H. Adams
Steven F. Bolling
Robert O. Bonow
Howard C. Herrmann
Nurse Planner
Michele Mistovich
To register and reserve housing, visit:
www.aats.org/valve